NDATOPICALLOTION
Approved
Aug 1982
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
5/8 — Partial
OVIDE (malathion) by Taro is cholinesterase inhibitors [moa]. First approved in 1982.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OVIDE (malathion) is a topical lotion cholinesterase inhibitor approved in 1982 for parasitic infections, primarily head lice. It works by inhibiting acetylcholinesterase, disrupting neurotransmission in target parasites. The product is a legacy small-molecule therapeutic approaching loss of exclusivity.
LOE Approaching3mo to LOE
Low commercial velocity with only 1 linked job posting; small product team focused on maintenance and compliance rather than growth initiatives.
Mechanism of Action
Cholinesterase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer
ER+/HER2- Early or Locally Advanced/Metastatic Breast Cancer
This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.
Non-Hodgkin's LymphomaHodgkin's DiseaseMultiple Myeloma
Expanded Access Program to Provide STC-15 to Patients With Selected Advanced Cancer
Cancer
A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak
0
Postherpetic Neuralgia
Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
Primary Hyperoxaluria
Worked on OVIDE at Taro? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.